Crossmark

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects

Crossref DOI link: https://doi.org/10.1080/13543784.2016.1255724

Published Online: 2016-11-18

Published Print: 2016-12

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Wynne, Christopher

Altendorfer, Mario

Sonderegger, Ivo

Gheyle, Lien

Ellis-Pegler, Rod

Buschke, Susanne

Lang, Benjamin

Assudani, Deepak

Athalye, Sandeep

Czeloth, Niklas
Funding

Funding for this research was provided by:

Boehringer Ingelheim (not applicable)
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieid20

Publication History

Received: 2016-08-31

Accepted: 2016-10-28

Published: 2016-11-18

Document is current

Any future updates will be listed below